Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2020

View Archived Issues

Dosing completed in phase I study of ML-004 as therapy for social deficit in ASD

Making exceptional responders unexceptional

Twist reports preclinical data on antibodies against S1 protein in SARS-CoV-2

FDA approves Xofluza for post-exposure prophylaxis of influenza

Capricor initiates dosing in phase II study of CAP-1002 in severe COVID-19

Genmab halts development of enapotamab vedotin

CTA for first-in-human study of FS-222 receives clearance in Spain

Cure Biopharma patents gemcitabine prodrugs for cancer

Incyte discloses new CDK2/cyclin E inhibitors

Snap Bio presents new Pim-1 and/or Pim-3 kinase inhibitors

Merck & Co. describes new nicotinic alpha7 receptor PAMs

Humabs BioMed divulges antibodies targeting influenza A HA protein

Tremfya approved in E.U. for active psoriatic arthritis

Final phase I/II data for PLX-9486 plus sunitinib in GIST

First-in-human data presented for Plasmodium falciparum transmission-blocking MAb

shMKK4-224: an MKK4 inhibitor for liver regeneration

Initial first-in-human data on BMS-986218 support further evaluation

Antimicrobial polymers AMP up fight against MDR bacteria

Phase III interim data reported on Sputnik V COVID-19 vaccine candidate

Treating Zika virus in a pregnant nonhuman primate model

Topline phase IIa data on vibegron in IBS show primary endpoint not met

FDA approves Oxlumo for primary hyperoxaluria type 1